1. Home
  2. CCSI vs CTNM Comparison

CCSI vs CTNM Comparison

Compare CCSI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consensus Cloud Solutions Inc.

CCSI

Consensus Cloud Solutions Inc.

N/A

Current Price

$43.00

Market Cap

684.3M

Sector

Technology

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$9.97

Market Cap

550.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CCSI
CTNM
Founded
2021
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
684.3M
550.7M
IPO Year
2022
2024

Fundamental Metrics

Financial Performance
Metric
CCSI
CTNM
Price
$43.00
$9.97
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
★ $50.00
$21.43
AVG Volume (30 Days)
108.7K
★ 659.1K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 0.46
EPS
★ 3.88
N/A
Revenue
★ $349,696,000.00
N/A
Revenue This Year
$3.40
N/A
Revenue Next Year
$4.22
N/A
P/E Ratio
$11.11
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$20.20
$6.73
52 Week High
$45.68
$17.79

Technical Indicators

Market Signals
Indicator
CCSI
CTNM
Relative Strength Index (RSI) 65.92 50.10
Support Level $33.37 $8.59
Resistance Level N/A $13.72
Average True Range (ATR) 2.06 0.81
MACD 0.67 0.30
Stochastic Oscillator 75.53 71.40

Price Performance

Historical Comparison
CCSI
CTNM

About CCSI Consensus Cloud Solutions Inc.

Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: